Costs of XXXX , metastatic to the bone, in the Netherlands.

@entity1 @entity263 @entity171 @entity174 @entity1745 @entity3 @entity158 @entity7634
OBJECTIVE: To quantify medical costs associated with bone @entity3 in @entity1 with @entity263 . Bone @entity3 in @entity1 with @entity263 are associated with considerable morbidity, negatively impact quality of life, and can add substantially to medical costs, given a median survival of 30-35 months from diagnosis of bone @entity3 . METHODS: A retrospective cost analysis from both a community and university hospital in The Netherlands was conducted. Twenty-eight @entity1 records (14 from each hospital) were investigated to assess the impact of skeletal-related events (SREs), including @entity174 , @entity1745 , and radiotherapy, on total direct medical costs and cost of hospitalization. Costs are given in @entity7634 ( @entity7634 ). RESULTS: The average total cost of treatment was @entity7634 13,051 per @entity1 over the 24-month follow-up period, which includes an average cost of @entity7634 6973 per @entity1 to treat SREs. Treatment of SREs more than doubled total treatment costs. @entity1 in this analysis experienced, on average, one SRE per year, and the cost of SREs varied from @entity7634 1187 to @entity7634 40,948. CONCLUSIONS: Occurrence of SREs contributes significantly to the cost of care for @entity1 with @entity263 . These data suggest that @entity171 , which can reduce @entity158 and SREs, may reduce healthcare costs.
